Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine challenge as a predictor of treatment response in mild to moderate Alzheimer's disease
NL-OMON38134Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Jun 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of galantamine in Alzheimer's disease (AD), sponsored by Centre for Human Drug Research. Primary endpoints: Adaptive tracking, Facial encoding and recognition task and 15 more. Started Jun 2011; status: active, not recruiting.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON38134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38134.